GlassScriptPhysician profile
Joseph M Petro
NPI 1154825263
$5,689.64
in general payments reported to CMS, 2019-2025
26 companies · $1,162 in 2025
The $1,162 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $115 · 2022: $768 · 2023: $1,749 · 2024: $1,896 · 2025: $1,162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,806.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $2,235.42 | 2023-2025 | |
| Abiomed | $360.43 | 2022-2025 | Impella |
| Biotronik INC. | $343.81 | 2025 | Biomonitor |
| Merck Sharp & Dohme LLC | $323.85 | 2021-2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $305.20 | 2021-2025 | Farxiga, Wainua, Brilinta |
| Janssen Pharmaceuticals, INC | $290.17 | 2022-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $289.87 | 2022-2025 | Jardiance |
| Inari Medical, INC. | $234.11 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Abbott Laboratories | $208.75 | 2022-2024 | Coroflow |
| Novartis Pharmaceuticals Corporation | $184.94 | 2022-2025 | |
| Pfizer INC. | $159.33 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $127.33 | 2022-2023 | Camzyos |
| Medtronic, INC. | $121.87 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $85.54 | 2023-2024 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $83.20 | 2024 | Arcalyst |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $78.57 | 2022-2024 | Kengreal, Cleviprex |
| Philips North America LLC | $64.00 | 2023-2024 | (5044) Mcot |
| Teleflex LLC | $30.21 | 2023 | Raider |
| Bracco Diagnostics INC. | $25.70 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $24.63 | 2023 | Evkeeza |
| Kls-Martin L.P. | $21.85 | 2024 | |
| Boston Scientific Corporation | $20.66 | 2023 | Watchman Access System |
| Medicomp INC | $19.80 | 2024 | Telepatch Cardiac Monitor |
| Cardiovascular Systems INC. | $17.84 | 2023 | |
| Heartflow, INC. | $17.61 | 2024 | |
| Novo Nordisk INC | $14.95 | 2023 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Petro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.